First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation
Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE® Therapy in Small Cell Lung Cancer
Read more at prnewswire.com